Tag Archive for: leucid bio

Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering

/in

Enables in vivo delivery of LEU011 harnessing the VivoCell PlatformTM  London, UK and Chicago, IL – 15 December 2025 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using its proprietary lateral CAR platform, and Syenex, an open-science genetic medicines platform company, today announced a strategic collaboration […]

Read more

Leucid Bio to Participate in Upcoming Healthcare Conferences

/in

London, UK – 31 October 2023 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company pursuing the development of innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company’s proprietary Lateral CAR platform, today announced that management will be participating in the following upcoming investor conferences during the month of November: BIO-Europe at Messe […]

Read more

Leucid Bio Granted MHRA Clinical Trial Authorisation for Lateral NKG2D CAR T-Cell Therapy LEU011

/in

Company on-track to dose first patient in LEU011 Phase 1/2 AERIAL trial during the fourth quarter of 2023 Lead programme, LEU011 previously awarded an Innovation Passport by MHRA for the treatment of solid tumours expressing NKG2D ligands London, UK – 21 September 2023 – Leucid Bio (“Leucid” or the “Company”), a privately-held biotechnology company pursuing […]

Read more

Leucid Bio Appoints Filippo Petti as Chief Executive Officer

/in

London, UK – 18 July 2023 – Leucid Bio (“Leucid” or the “Company”), a biotech company pursuing a differentiated approach to develop next generation Chimeric Antigen Receptor T-cell (CAR-T) therapies using the Company’s proprietary Lateral CAR platform, today announced the appointment of Filippo Petti as its Chief Executive Officer, with immediate effect. Mr. Petti has […]

Read more

Leucid Bio and Great Ormond Street Hospital enter commercial agreement at new gene therapy manufacturing centre

/in

Agreement to manufacture Leucid Lead asset, LEU011 for the treatment of solid tumours and haematological malignancies utilising facilities and quality assurance services at the Zayed Centre for Research into Rare Disease in Children is first-of-its-kind. Leucid Bio to retain IP in respect of services arising from this venture. Leucid Bio expects to file its CTA […]

Read more